SLC5A2 and heart failure: Both SGLT2 inhibitors and MRAs significantly reduced the risk of worsening heart failure events (SGLT2 inhibitors by 25.21% and MRAs by 17.93%) and cardiovascular deaths (SGLT2 inhibitors by 14.36% and MRAs by 7.16%) when compared to placebo.